Some physicians suggest tofacitinib, a small molecule compound target JAK1 and JAK3, could be applied in the treatment of COVID-19, and tofacitinib success in treating a COVID-19 patient complicated with ulcerative colitis (134). The gene discussed is JAK3; the disease is COVID-19.